STOCK TITAN
  1. Home
  2. News
  3. VERU

Veru Inc - VERU STOCK NEWS

Welcome to our dedicated news page for Veru (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.

News
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11, 2024. The presentations focus on Enobosarm, a potential weight loss medication that aims to reduce fat mass while preserving muscle in older patients with obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
conferences
-
News
Veru Announces Date of 2024 Annual Meeting of Shareholders
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) filed its 2023 Form 10-K/A and Q1 2024 Form 10-Q, rescheduling the Annual Meeting of Shareholders to June 18, 2024. The company focuses on innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
News
Veru Reschedules Annual Meeting of Shareholders
Rhea-AI Summary
Veru Inc. reschedules its 2024 Annual Meeting of Shareholders to allow time for reviewing restated financial statements. The company is in the process of restating historical financial statements, with expected filings by April 15, 2024. Research and development expenses were overestimated, leading to an extended cash runway for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
none
News
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Rhea-AI Summary
Veru Inc. appoints Dr. Louis Aronne as Chief Medical Advisor to support the advancement of enobosarm, a novel drug for quality weight loss. Dr. Aronne's expertise in obesity treatment enhances Veru's development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
management
-
News
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Rhea-AI Summary
Veru Inc. received a delinquency notification from Nasdaq due to non-compliance with filing its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance, with a potential extension until August 19, 2024. The delay was caused by higher estimated research and development expenses, leading to a longer cash runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
News
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Rhea-AI Summary
Veru Inc. forms a Scientific Advisory Board to support the development of enobosarm, a novel drug for quality weight loss. The board comprises experts in metabolic diseases, obesity, and muscle preservation, aiming to enhance fat loss while preserving muscle mass.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
News
Veru Reports Fiscal 2024 First Quarter Financial Highlights
Rhea-AI Summary
Veru Inc. receives FDA clearance for enobosarm development in combination with GLP-1 drugs for higher quality weight loss, plans to initiate Phase 2b obesity study by April 2024. Completed public offering for net proceeds of $35.2 million, bringing total cash to $40.6 million at December 31, 2023. Company to host conference call and webcast today at 8:00 a.m. ET. Mitchell Steiner, M.D., Chairman, President, and CEO of Veru Inc., emphasizes the critical unmet medical need for higher quality weight loss therapeutics that preserve muscle and augment fat loss with minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
earnings
-
News
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) has received FDA clearance for its Investigational New Drug (IND) application for a Phase 2b clinical study to evaluate enobosarm, a selective androgen receptor modulator (SARM), in combination with GLP-1 drugs for weight loss. The trial aims to preserve muscle mass and physical function while increasing fat loss in sarcopenic obese or overweight elderly patients. The study is expected to begin by April 2024, with topline results anticipated by the end of 2024. Enobosarm's potential to prevent muscle loss and reduce fat in at-risk patients presents a significant opportunity for the company's innovative medicines in the weight loss, oncology, and viral induced ARDS segments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.2%
Tags
clinical trial
-
News
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Veru Inc. announces an update of its Phase 2b clinical program of enobosarm to augment fat loss and avoid muscle loss when combined with GLP-1 drugs for weight loss at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be made by Mitchell Steiner, M.D., Chairman, President, and CEO of Veru, on February 14, 2024. The webcast will be accessible through the Investors section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
News
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
Rhea-AI Summary
Veru Inc. (VERU) will host a conference call and audio webcast on February 8, 2024, to discuss its fiscal 2024 first-quarter financial results and provide a business update. The company is a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral-induced acute respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
conferences earnings
Stock VERU logo
Veru Inc

Nasdaq:VERU

VERU Rankings

#3830 Ranked by Market Cap
#5486 Ranked by Stock Gains
N/A Ranked by Dividends

VERU Stock Data

222.50M
112.01M
14.11%
40.25%
6.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miami

About VERU

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries